Are You Eligible for a Clinical Trial? ChatGPT can Find Out

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates.

Researchers at UT Southwestern Medical Centre used ChatGPT to assess whether patients were eligible to take part in clinical trials and were able to identify suitable candidates within minutes.

Clinical trials, which test new medications and procedures on the public, are vital for developing and validating new treatments. But many trials struggle to enrol enough participants. According to a recent study, up to 20% of National Cancer Institute (NCI)-affiliated trials fail due to low enrolment. This not only inflates costs and delays results, but also undermines the reliability of new treatments.

Currently, screening patients for trials is a manual process. Researchers must review each patient’s medical records to determine if they meet eligibility criteria, which takes around 40 minutes per patient. With limited staff and resources, this process is often too slow to keep up with demand.

Part of the problem is that valuable patient information contained in electronic health records (EHRs) is often buried in unstructured text, such as doctors’ notes, which traditional machine learning software struggles to decipher. As a result, many eligible patients are overlooked because there simply isn’t enough capacity to review every case. This contributes to low enrolment rates, trial delays and even cancellations, ultimately slowing down access to new therapies.

To counter this problem, the researchers have looked at ways of speeding up the screening process by using ChatGPT. Researchers used GPT-3.5 and GPT-4 to analyse 74 patients’ data to see if they qualified for a head and neck cancer trial.

Three ways of prompting the AI were tested:

  • Structured Output (SO): asking for answers in a set format.
  • Chain of Thought (CoT): asking the model to explain its reasoning.
  • Self-Discover (SD): letting the model figure out what to look for.

The results were promising. GPT-4 was more accurate than GPT-3.5, though slightly slower and more expensive. Screening times ranged from 1.4 to 12.4 minutes per patient, with costs between $0.02 and $0.27.

"LLMs like GPT-4 can help screen patients for clinical trials, especially when using flexible criteria," said Dr. Mike Dohopolski, lead author of the study. "They’re not perfect, especially when all rules must be met, but they can save time and support human reviewers."

This research highlights the potential for AI to support faster, more efficient clinical trials - bringing new treatments to patients sooner.

The study is one of the first articles published in IOP Publishing's Machine Learning series™, the world’s first open access journal series dedicated to the application and development of machine learning (ML) and artificial intelligence (AI) for the sciences.

The same research team have worked on a method that allows surgeons to adjust patients’ radiation therapy in real time whilst they are still on the table. Using a deep learning system called GeoDL, the AI delivers precise 3D dose estimates from CT scans and treatment data in just 35 milliseconds. This could make adaptive radiotherapy faster and more efficient in real clinical settings.

Jacob Beattie et al.
ChatGPT augmented clinical trial screening.
Mach. Learn.: Health, 2025. doi: 10.1088/3049-477X/adbd47

Most Popular Now

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...

Digital ECGs at Barts Health: A High-Imp…

Opinion Article by Dr Krishnaraj Sinhji Rathod, consultant in interventional cardiology, Barts Health NHS Trust. Picture the moment. A patient in an ambulance, enroute to hospital with new chest pain. Paramedics...

International Study Reveals Sex and Age …

An international research team led by Assistant Professor Zhiyu Wan from ShanghaiTech University has recently published groundbreaking findings in the journal Health Data Science, highlighting biases in multimodal large language...

Study Sheds Light on Hurdles Faced in Tr…

Implementing artificial intelligence (AI) into NHS hospitals is far harder than initially anticipated, with complications around governance, contracts, data collection, harmonisation with old IT systems, finding the right AI tools...

Using Deep Learning for Precision Cancer…

Altuna Akalin and his team at the Max Delbrück Center have developed a new tool to more precisely guide cancer treatment. Described in a paper published in Nature Communications, the...

New AI Approach Paves Way for Smarter T-…

Researchers have harnessed the power of artificial intelligence (AI) to tackle one of the most complex challenges in immunology: predicting how T cells recognize and respond to specific peptide antigens...

Study Used AI Models to Improve Predicti…

Chronic kidney disease (CKD) is a complex condition marked by a gradual decline in kidney function, which can ultimately progress to end-stage renal disease (ESRD). Globally, the prevalence of the...